Algok Bio Inc, a global new drug development subsidiary of KPS, and the Korea Atomic Energy Research Institute announced on the 19th that they will present research results on the 'TM4SF4' target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback